{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T12:09:03Z","timestamp":1676376543844},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12876-017-0585-x","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T23:33:42Z","timestamp":1487028822000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature"],"prefix":"10.1186","volume":"17","author":[{"given":"Catherine","family":"Atkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Earwaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Pallan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shishir","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Punia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuk Ting","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"key":"585_CR1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/0974-777X.52979","volume":"1","author":"LJ Oliveria Andrade de","year":"2009","unstructured":"de Oliveria Andrade LJ, D\u2019Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Paran\u00e1 R. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis. 2009;1:33\u20137.","journal-title":"J Glob Infect Dis"},{"key":"585_CR2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"585_CR3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"585_CR4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-230X-11-4","volume":"11","author":"R Sacco","year":"2011","unstructured":"Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E, et al. Complete response for advanced liver cancer during sorafenib therapy: case report. BMC Gastroenterol. 2011;11:4.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"585_CR5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3892\/ol.2013.1131","volume":"5","author":"AM Gerardi","year":"2013","unstructured":"Gerardi AM, Stoppino LP, Liso A, Macarini L, Landriscina M. Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma. Oncol Lett. 2013;5(3):975\u20137.","journal-title":"Oncol Lett"},{"key":"585_CR6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol. 2012;57:821\u20139.","journal-title":"J Hepatol"},{"issue":"32","key":"585_CR7","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","volume":"31","author":"AL Cheng","year":"2013","unstructured":"Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067\u201375.","journal-title":"J Clin Oncol"},{"issue":"28","key":"585_CR8","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","volume":"31","author":"PJ Johnson","year":"2013","unstructured":"Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517\u201324.","journal-title":"J Clin Oncol"},{"issue":"3","key":"585_CR9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1078-0432.CCR-09-2123","volume":"16","author":"C Braconi","year":"2010","unstructured":"Braconi C, Valeri N, Gasperini P, Huang N, Taccioli C, Nuovo G, et al. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin Cancer Res. 2010;16(3):957\u201366.","journal-title":"Clin Cancer Res"},{"key":"585_CR10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2015.03.012","volume":"118","author":"V Descamps","year":"2015","unstructured":"Descamps V, Helle F, Louandre C, Martin E, Brochot E, Izquierdo L, et al. The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro. Antiviral Res. 2015;118:93\u2013102.","journal-title":"Antiviral Res"},{"key":"585_CR11","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1136\/gut.2009.182212","volume":"58","author":"K Himmelsbach","year":"2009","unstructured":"Himmelsbach K, Sauter D, Baumert TF, Ludwig L, Blum HE, Hildt E. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut. 2009;58:1644\u201353.","journal-title":"Gut"},{"issue":"1","key":"585_CR12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/apt.12098","volume":"37","author":"R Cabrera","year":"2013","unstructured":"Cabrera R, Limaye AR, Horne P, Mills R, Soldevila-Pico C, Clark V, et al. The antiviral effect of sorafenib in hepatitis c-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2013;37(1):91\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"585_CR13","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43\u20139006 exhibits broad spectrum oral antitumour activity and targets the raf\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor proliferation and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"585_CR14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000319831","volume":"3","author":"T Nakazawa","year":"2010","unstructured":"Nakazawa T, Hidaka H, Shibuya A, Koizumi W. Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases. Case Rep Oncol. 2010;3:298\u2013303.","journal-title":"Case Rep Oncol"},{"issue":"3","key":"585_CR15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/039463201002300332","volume":"23","author":"G Lorenzo Di","year":"2010","unstructured":"Di Lorenzo G, Imbimbo M, Leopardo D, Marciano R, Federico P, Buonerba C, et al. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient. Int J Immunopathol Pharmacol. 2010;23(3):951\u20134.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"Suppl 1","key":"585_CR16","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1007\/s12032-010-9669-y","volume":"28","author":"L Chelis","year":"2011","unstructured":"Chelis L, Ntinos N, Souftas V, Deftereos S, Xenidis N, Chamalidou E, et al. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report. Med Oncol. 2011;28 Suppl 1:S165\u20138.","journal-title":"Med Oncol"},{"issue":"Suppl 1","key":"585_CR17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000333279","volume":"81","author":"T Inuzuka","year":"2011","unstructured":"Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S, Sakamoto A, et al. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology. 2011;81 Suppl 1:152\u20137.","journal-title":"Oncology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-017-0585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T16:46:39Z","timestamp":1568825199000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-017-0585-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,14]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["585"],"URL":"https:\/\/doi.org\/10.1186\/s12876-017-0585-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,14]]},"article-number":"30"}}